直接就诊与转诊的大面积缺血性卒中患者血管内取栓治疗效果:SELECT2 试验预设分析
SELECT2 试验预设分析纳入 352 例大面积缺血性卒中患者,比较直接就诊与转诊患者接受血管内取栓(EVT)与药物管理的疗效。直接就诊者和转诊者均从 EVT 获益,无显著异质性(交互作用 P=0.14),但直接就诊者点估计值更高;转诊时间延长和缺血改变进展与更差 EVT 结局相关。
要点
- 直接就诊患者接受 EVT 的调整广义 OR 为 2.01(95%CI 1.42-2.86)。
- 转诊患者接受 EVT 的调整广义 OR 为 1.50(95%CI 1.11-2.03),交互作用 P=0.14。
- 转诊时间≥3 小时者 EVT 调整广义 OR 为 1.15(95%CI 0.73-1.80)。
核心结论
- SELECT2 试验中直接就诊和转诊的大面积缺血性卒中患者均从 EVT 获益,包括转诊医院 ASPECTS 较低者;但直接就诊者 EVT 与更好功能结局的关联在数值上更佳。
研究设计与样本
- SELECT2 试验的预设二次分析,评估 EVT 与药物管理在大面积缺血性卒中患者中的疗效。
- 纳入 18 至 85 岁急性缺血性卒中患者,因颈内动脉或大脑中动脉 M1 段闭塞,且 ASPECTS 3 至 5 分、影像核心≥50 mL 或两者兼有。
- 2019 年 10 月至 2022 年 9 月从美国、加拿大、欧洲、澳大利亚和新西兰的 31 个具备 EVT 能力的中心入组,共 352 例。
- 数据于 2023 年 8 月至 2024 年 1 月分析。
主要发现
- 352 例入组患者中 145 例(41.2%)为女性,中位(IQR)年龄 66.5(58-75)岁。
- 211 例(59.9%)为转诊患者,141 例(40.1%)为直接就诊患者;中位(IQR)转诊时间 178(136-230)分钟。
- 中位(IQR)ASPECTS 从转诊医院(5[4-7])降至具备 EVT 能力的中心(4[3-5])。
- 直接就诊患者调整广义 OR 2.01(95%CI 1.42-2.86),转诊患者调整广义 OR 1.50(95%CI 1.11-2.03),交互作用 P=0.14。
- 转诊医院 ASPECTS≤5 的 82 例转诊患者中 44 例接受 EVT,调整广义 OR 1.52(95%CI 0.89-2.58);每丢失 1 分 ASPECTS 的调整广义 OR 0.89(95%CI 0.77-1.02);转诊时间≥3 小时者调整广义 OR 1.15(95%CI 0.73-1.80)。
临床怎么用
- 原文结论强调需要快速识别适合转诊的患者并加速转运。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with large ischemic core stroke have poor clinical outcomes and are frequently not considered for interfacility transfer for endovascular thrombectomy (EVT). OBJECTIVE: To assess EVT treatment effects in transferred vs directly presenting patients and to evaluate the association between transfer times and neuroimaging changes with EVT clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: This prespecified secondary analysis of the SELECT2 trial, which evaluated EVT vs medical management (MM) in patients with large ischemic stroke, evaluated adults aged 18 to 85 years with acute ischemic stroke due to occlusion of the internal carotid or middle cerebral artery (M1 segment) as well as an Alberta Stroke Program Early CT Score (ASPECTS) of 3 to 5, core of 50 mL or greater on imaging, or both. Patients were enrolled between October 2019 and September 2022 from 31 EVT-capable centers in the US, Canada, Europe, Australia, and New Zealand. Data were analyzed from August 2023 to January 2024. INTERVENTIONS: EVT vs MM. MAIN OUTCOMES AND MEASURES: Functional outcome, defined as modified Rankin Scale (mRS) score at 90 days with blinded adjudication. RESULTS: A total of 958 patients were screened and 606 patients were excluded. Of 352 enrolled patients, 145 (41.2%) were female, and the median (IQR) age was 66.5 (58-75) years. A total of 211 patients (59.9%) were transfers, while 141 (40.1%) presented directly. The median (IQR) transfer time was 178 (136-230) minutes. The median (IQR) ASPECTS decreased from the referring hospital (5 [4-7]) to an EVT-capable center (4 [3-5]). Thrombectomy treatment effect was observed in both directly presenting patients (adjusted generalized odds ratio [OR], 2.01; 95% CI, 1.42-2.86) and transferred patients (adjusted generalized OR, 1.50; 95% CI, 1.11-2.03) without heterogeneity (P for interaction = .14). Treatment effect point estimates favored EVT among 82 transferred patients with a referral hospital ASPECTS of 5 or less (44 received EVT; adjusted generalized OR, 1.52; 95% CI, 0.89-2.58). ASPECTS loss was associated with numerically worse EVT outcomes (adjusted generalized OR per 1-ASPECTS point loss, 0.89; 95% CI, 0.77-1.02). EVT treatment effect estimates were lower in patients with transfer times of 3 hours or more (adjusted generalized OR, 1.15; 95% CI, 0.73-1.80). CONCLUSIONS AND RELEVANCE: Both directly presenting and transferred patients with large ischemic stroke in the SELECT2 trial benefited from EVT, including those with low ASPECTS at referring hospitals. However, the association of EVT with better functional outcomes was numerically better in patients presenting directly to EVT-capable centers. Prolonged transfer times and evolution of ischemic change were associated with worse EVT outcomes. These findings emphasize the need for rapid identification of patients suitable for transfer and expedited transport. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03876457.
引用
- Sarraj A, Hill MD, Hussain MS, et al. Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes: A Prespecified Analysis of the SELECT2 Trial. JAMA Neurol. 2024. PMID: 38363872. doi:10.1001/jamaneurol.2024.0206
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。